6 February 2025 The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted by UK obesity group Verdiva Bio, but what Orbis’s VC round does show is the growing interest in macrocyclics as a drug class.
Russia is experiencing a sharp growth in the demand for drugs against diabetes this year, particular those that are also used for weight loss, reports The Pharma Letter’s local correspondent. 4 February 2025
US President Donald Trump has implemented a series of tariffs on imports from Canada, Mexico and China, but the additional taxes could affect the price Americans pay for generic drugs, with pharma trade groups expressing their fears about the consequences. 4 February 2025
Russia plans to significantly expand the geography of the export of its drugs this year, paying attention both to emerging nations and developed countries, reports The Pharma Letter’s local correspondent. 3 February 2025
Swiss generic and biosimilars drugmaker Sandoz today revealed that Francisco Ballester, president Region International and a member of the Sandoz executive committee, will retire and step down from the SEC on March 1, 2025. 3 February 2025
This article explores the latest conversations around generic topical and transdermal drug delivery systems (TDS) in the US Food and Drug Administration’s (FDA dermal pharmacology space, delving into recent guidance updates and examining the challenges facing the development of generic TDS. 21 January 2025
Several of the USA’s biggest pharmacy benefit managers (PBMs) have generated billions of dollars in revenue by charging “enormous mark-ups,” according to the competition regulator. 15 January 2025
Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto (sacubitril/valsartan) combination patent. 14 January 2025
India's Parliamentary panel has come down heavily on the National Pharmaceutical Pricing Authority (NPPA) and directed it to provide a detailed report explaining the recent 50% price increase on 11 essential drug formulations. 30 December 2024
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
The US Court of Appeals for the Federal Circuit on Friday affirmed a lower district court order against Israeli pharmaceutical maker Teva Pharmaceutical Industries requiring its US subsidiary to delist several asthma inhaler patents from the Food and Drug Administration’s (FDA) Orange Book. 23 December 2024
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
Swiss generic and biosimilar medicines major Sandoz today announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. 17 December 2024
Shares of Swedish pharma firm Orexo leapt 20.2% to 20.60 kronor this morning, following its announcement over the weekend that is has reached a settlement agreement with India’s Sun Pharmaceutical Industries to resolve the patent litigation regarding Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII), for the treatment of opioid use disorder in the USA. 16 December 2024
Israeli drugmaker Teva Pharmaceutical Industries has entered into an agreement with JKI - established by the fund managed and operated by J-Will - whereby all shares of Teva Takeda Pharma Limited and its wholly-owned subsidiary, Teva Takeda Yakuhin, will be transferred to JKI. 6 December 2024
Sino-American oncology company BeOne Medicines, until now known as BeiGene, has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Brukinsa (zanubrutinib) in the USA. 25 November 2024
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Global drugmakers are losing their market share in the Russian market for erectile dysfunction drug, which is rapidly being taken over by local players, reports The Pharma Letter’s local correspondent. 23 April 2024
Indian pharma exports to the US market are rebounding strongly in the current fiscal year, showing a notable double-digit growth after a lull. 23 April 2024
The USA’s Association for Accessible Medicines (AAM), the trade association that represents generic and biosimilar drug manufacturers, commented on an analysis released by Avalere showing that Medicare plans increase patient costs for generic medicines by moving those medicines to more expensive formulary tiers. 20 April 2024
Indian drugmaker Biocon has entered an exclusive licensing and supply agreement with Brazil’s Biomm for the commercialization of its vertically integrated drug product, semaglutide. 18 April 2024
The prices of certain active pharmaceutical ingredients (APIs) have experienced a significant decline over the past two months, as compared to the elevated prices reigning during the Covid pandemic. 18 April 2024
The Russian government is considering designing additional measures aimed at creating conditions for the growth of domestic pharmaceutical market during the period of 2024-2025, reports The Pharma Letter’s local correspondent. 17 April 2024
Canada-based Bausch Health, and its gastroenterology business Salix Pharmaceuticals, announced that the US Court of Appeals for the Federal Circuit announced a positive ruling on its patent dispute with Norwich Pharmaceuticals. 12 April 2024
For the last three decades, the availability of cost-effective generic medicines has driven increased access to life-saving treatments for millions of patients in Europe. 10 April 2024
The Russian drugmaker Geropharm says it plans to launch a generic copy of Danish drugmaker Novo Nordisk’s Wegovy (semaglutide) for the treatment of obesity, reports The Pharma Letter’s local correspondent. 9 April 2024
Canada-based Bausch Health saw its shares rise 3.6% to $10.41 after it revealed that, along with its gastroenterology unt Salix Pharmaceuticals, it has filed a lawsuit today in the US District Court for the District of New Jersey against Amneal Pharmaceuticals and its subsidiaries. 6 April 2024
The Russian government will launch a project aimed at creating generic copies of patented original drugs, according to recent statements made by the deputy head of the Ministry of Industry and Trade, Ekaterina Priezzheva. 4 April 2024
The US Food and Drug Administration (FDA) yesterday published the draft guidance for industry, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.” 3 April 2024
India’s Biocon says that it has received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its complex formulation liraglutide (6mg/ml solution for injection in pre-filled pen). 2 April 2024
The Indian pharmaceutical sector is poised for a substantial makeover with the inauguration of 27 greenfield plants dedicated to manufacturing bulk drugs. 2 April 2024
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
The US Federal Trade Commission revealed on Friday that it has filed an amicus brief explaining that pharmaceutical maker Teva Pharmaceutical Industries has improperly listed patents in the Orange Book and urged the court to order those listings removed. 25 March 2024